SAN CARLOS, Calif., April 28, 2015 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced its pleasure to be lead partner for the European conference in the exciting field of Quantitative Systems Pharmacology (QSP). The conference focuses on uses and benefits of QSP in pharmaceutical drug development.
Rosa's lead sponsorship is the second of multiple major QSP specific conference sponsorships in 2015 intended to further expand the adoption of QSP. In recent years, QSP has proven to be a fundamentally important research approach that delivers greater scientific insight and better informs discovery and development decisions. The most innovative R&D organizations in the industry are rapidly adopting this significant research approach.
Dr. Ananth Kadambi will present the Keynote Address at the QSP Congress covering the philosophical and practical role of QSP in the scientific process, common R&D applications and key aspects of QSP market adoption. Additionally, Dr. Mike Reed will present a significant case study covering creating and performing research with PhysioPD™ Research Platforms. Rosa will also participate in two panel discussions on current and future applications.
"Rosa & Co. is honored to be the lead sponsor for this conference devoted solely to QSP. This important event reflects the fact that QSP is increasingly seen by the industry as a proven approach for enhancing drug development."
- Dr. Ron Beaver
About Rosa Rosa supports clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical PhysioPD™ Research Platforms. These Platforms are customized to allow clients to simulate normal and disease physiology, drug action, patient variability and trial outcomes, and efficiently answer the full spectrum of questions related to targets, mechanisms and outcomes. Rosa's clients participate in Platform creation and biological simulation research, and retain the Platforms to perform additional program research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to optimize drug development and has completed hundreds of engagements with clients in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area expertise in oncology, immuno-oncology, inflammation, autoimmunity, metabolism, cardiovascular, dermatology, central nervous system, metabolism, cardiovascular, antibacterial and antiviral biology. For more information, visit http://www.rosaandco.com/news.html.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
Media Contact: Stephanie Sherman Email 425-591-5738